BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma
- PMID: 4270384
- PMCID: PMC2481055
BCG vaccination of children against leprosy: seven-year findings of the controlled WHO trial in Burma
Abstract
A controlled study of the efficacy of BCG vaccination for the prevention of leprosy began in Burma at the end of August 1964. This paper presents the findings after 7 years-i.e., the results of 6 annual follow-up examinations up to the end of June 1971. The incidence rate in BCG-vaccinated children 0-4 years of age at intake was lower than that in children in the control group. The protection conferred by BCG was relatively low (44%) and applied only to early cases of leprosy, the great majority tuberculoid cases. BCG vaccination did not protect household contacts or children 5-14 years of age who were not exposed in the household. This reduction must be interpreted in the light of several factors: form of leprosy, bacterial status, lepromin reactivity, evolution of cases, and level of endemicity. Consequently it does not seem probable that the reduction in incidence would substantially affect the pattern or trend of the disease in an area similar to that where the study is being carried out; the probability would be much lower if not nil in regions of relatively low endemicity (1-2 per 1 000 or less).
Similar articles
-
BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma.Bull World Health Organ. 1985;63(6):1069-78. Bull World Health Organ. 1985. PMID: 2940028 Free PMC article. Clinical Trial.
-
BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.Bull World Health Organ. 1974;51(1):93-9. Bull World Health Organ. 1974. PMID: 4281729 Free PMC article. Clinical Trial.
-
BCG vaccination of children against leprosy. Preliminary findings of the WHO-controlled trial in Burma up to January 1970.Int J Lepr Other Mycobact Dis. 1971 Apr-Jun;39(2):609. Int J Lepr Other Mycobact Dis. 1971. PMID: 4260184 Clinical Trial. No abstract available.
-
ILEP organisations should strive for high BCG coverage in communities at risk of leprosy.Lepr Rev. 2007 Jun;78(2):88-101. Lepr Rev. 2007. PMID: 17824479 Review.
-
BCG vaccination in mycobacterial infections.Br Med Bull. 1969 May;25(2):183-8. doi: 10.1093/oxfordjournals.bmb.a070690. Br Med Bull. 1969. PMID: 4248333 Review. No abstract available.
Cited by
-
Leprosy.Clin Microbiol Rev. 1988 Jul;1(3):330-48. doi: 10.1128/CMR.1.3.330. Clin Microbiol Rev. 1988. PMID: 3058299 Free PMC article. Review.
-
In vitro lymphocyte response to purified protein derivative, BCG and Mycobacterium leprae in a population not exposed to leprosy.Infect Immun. 1975 Jun;11(6):1163-9. doi: 10.1128/iai.11.6.1163-1169.1975. Infect Immun. 1975. PMID: 1095479 Free PMC article.
-
Efficacy of leprosy vaccines across the globe: A systematic review & meta-analysis of randomized controlled trials.Indian J Med Res. 2024 Sep&Oct;160(3&4):293-302. doi: 10.25259/IJMR_1289_2024. Indian J Med Res. 2024. PMID: 39632641 Free PMC article.
-
BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma.Bull World Health Organ. 1985;63(6):1069-78. Bull World Health Organ. 1985. PMID: 2940028 Free PMC article. Clinical Trial.
-
In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation.Clin Exp Immunol. 1983 Apr;52(1):29-37. Clin Exp Immunol. 1983. PMID: 6190596 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources